- Home
- ABTS vs KZIA Comparison
ABTS vs KZIA Comparison
Compare ABTS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- KZIA
- Stock Information
- Founded
- ABTS 2010
- KZIA 1994
- Country
- ABTS Hong Kong
- KZIA Australia
- Employees
- ABTS N/A
- KZIA N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- ABTS Technology
- KZIA Health Care
- Exchange
- ABTS Nasdaq
- KZIA Nasdaq
- Market Cap
- ABTS 9.8M
- KZIA 5.1M
- IPO Year
- ABTS N/A
- KZIA 1999
- Fundamental
- Price
- ABTS $5.09
- KZIA $6.58
- Analyst Decision
- ABTS
- KZIA Strong Buy
- Analyst Count
- ABTS 0
- KZIA 2
- Target Price
- ABTS N/A
- KZIA $57.50
- AVG Volume (30 Days)
- ABTS 50.8K
- KZIA 2.6M
- Earning Date
- ABTS 08-16-2025
- KZIA 07-07-2025
- Dividend Yield
- ABTS N/A
- KZIA N/A
- EPS Growth
- ABTS N/A
- KZIA N/A
- EPS
- ABTS N/A
- KZIA N/A
- Revenue
- ABTS $6,711,225.00
- KZIA $1,549,158.00
- Revenue This Year
- ABTS N/A
- KZIA N/A
- Revenue Next Year
- ABTS N/A
- KZIA N/A
- P/E Ratio
- ABTS N/A
- KZIA N/A
- Revenue Growth
- ABTS 299.11
- KZIA 248983.08
- 52 Week Low
- ABTS $1.35
- KZIA $2.86
- 52 Week High
- ABTS $14.10
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- ABTS 64.83
- KZIA 51.85
- Support Level
- ABTS $3.53
- KZIA $5.98
- Resistance Level
- ABTS $4.28
- KZIA $6.65
- Average True Range (ATR)
- ABTS 0.53
- KZIA 0.93
- MACD
- ABTS 0.03
- KZIA -0.30
- Stochastic Oscillator
- ABTS 87.12
- KZIA 17.24
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.